Pre-made Indatuximab benchmark antibody ( Whole mAb ADC, anti-SDC1 therapeutic antibody, Anti-SDC/CD138/SYND1/syndecan Antibody) for drug discovery and mechanism of action (MOA) research

Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

Order information

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

Catalog No.	Package	Price(In USD)	Qty (Quantity)	Sum(In USD)
GMP-Bios-ab-271-1mg	1mg	Inquiry
GMP-Bios-ab-271-10mg	10mg	Inquiry
GMP-Bios-ab-271-100mg	100mg	Inquiry
GMP-Bios-ab-271-xmg	≥100mg	Inquiry
			Shipping Cost:	760.00
			Total:

Description

Products Name (INN Index)	Pre-Made Indatuximab biosimilar, Whole mAb ADC, Anti-SDC1 Antibody: Anti-SDC/CD138/SYND1/syndecan therapeutic antibody
INN Name	Indatuximab
Target	SDC1
Format	Whole mAb ADC
Derivation
Species Reactivity	Human
CH1 Isotype	IgG4
VD LC	Kappa
Highest_Clin_Trial (Jan '20)	Phase-II
Est. Status	Discontinued
100% SI Structure	None
99% SI Structure	None
95-98% SI Structure	None
Year Proposed	2011
Year Recommended	2012
Companies	Biotest AG
Conditions Approved	na
Conditions Active	na
Conditions Discontinued	na
Development Tech	na